Trial Profile
30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Pulmonary embolism; Venous thromboembolism; Venous thrombosis
- Focus Adverse reactions
- Acronyms EINSTEINJr
- Sponsors Bayer
- 15 Jun 2019 Planned number of patients changed from 20 to 40.
- 07 Jun 2019 Trial has been completed in UK.
- 03 May 2017 Status changed from recruiting to completed.